PW Consulting Forecasts Prostate Biopsy Devices Market to Expand at 8.5% CAGR Through 2032

Prostate Biopsy Devices Market — Strategic Outlook for 2026: A PW Consulting Intelligence Brief

Executive summary

PW Consulting’s latest market study (base year: 2025; historical window: 2020–2025; forecast: 2026–2032) delivers a targeted playbook for commercial, clinical and corporate leaders shaping prostate biopsy device strategy in 2026. The market has expanded from an estimated USD 175.8 Million in 2020 to USD 262.6 Million in 2025, and our forecast modeling projects continued expansion to approximately USD 462.5 Million by 2032. The underlying compound annual growth rate (CAGR) for the forecast period is 8.5% — a signal that this is a mid-cycle growth opportunity driven by technology upgrades, reimbursement realignment and accelerating clinical adoption of transperineal approaches and image-guided systems.
Prostate Biopsy Devices Market

Why this report is immediately material to 2026 decision-making

• Timing matters: the market is at a regulatory and coding inflection point. Effective January 1, 2026, CPT code 55700 was replaced with a set of new Category I codes that explicitly bundle imaging guidance with biopsy procedures. This re-bundling changes the economics of device procurement, vendor contracting and hospital value analyses.
  Prostate Biopsy Devices Market

• Reimbursement clarity for specific transperineal codes (including a newly highlighted code for ultrasound-guided transperineal biopsy) has already influenced payer coverage policies; manufacturers and hospital systems must align pricing, clinical evidence and billing pathways now to capture near-term adoption.
  Prostate Biopsy Devices Market

• Technology convergence—fusion navigation platforms, AI histopathology, and procedure-specific access systems—means product roadmaps and partnership strategies formed in 2026 will determine competitive positioning throughout the forecast window.

• Market structure is neither atomized nor monopolistic. Concentration metrics indicate that leading firms control a meaningful share of demand, but there remains ample whitespace for differentiated entrants and vertically integrated solutions.

Market dynamics and growth drivers

Our analysis synthesizes macro demand signals with granular adoption patterns to isolate the principal growth drivers for 2026 and beyond. Key forces include:

• Clinical practice shifts toward transperineal biopsy to reduce infection risk and meet emerging guideline preferences, supported by reimbursement updates that make transperineal workflows economically viable for many institutions.

• Upgrading of imaging and navigation capabilities (MRI/ultrasound fusion and real-time tracking) that increase diagnostic yield and create value propositions for bundled device–software offerings.

• Rapid incorporation of AI into pathology and imaging workflows—clearances in 2024–2025 for AI-powered pathology tools and navigation systems have reduced technical risk and accelerated procurement discussions.

• Health system purchasing dynamics: hospital networks are conducting systemwide value analyses (case in point: a notable hospital network’s adoption of a novel biopsy platform in early 2026) that favor bundled capital + disposables contracts with predictable recurring revenue.

• Regulatory momentum in 2025–2026 (including new device clearances and pathway approvals) has lowered barriers for entrants with differentiated clinical data or integration-ready platforms.

Competitive landscape — where incumbents and challengers are placing their bets

The competitive map is populated by device OEMs, navigation and imaging vendors, niche access-system specialists, and new entrants leveraging AI. Selected strategic positions of core companies covered in the analysis:

• Argon Medical Devices, Inc. — Known for robust core biopsy instrument portfolios, Argon’s strength lies in a broad, procedure-centric catalog that is attractive to institutions seeking compatibility and scale. Their product-line focus supports rapid adoption in existing purchasing contracts.

• B. Braun — As a longstanding medical device supplier with global reach, B. Braun leverages distribution and clinical training capabilities to push disposable needle systems that integrate easily into established workflows.

• Boston Scientific Corporation — With deep capital equipment and disposables capabilities, Boston Scientific competes on system-level solutions and strategic relationships with health systems that favor bundled acquisitions and service agreements.

• CIVCO Medical Solutions — Positioned in the access-guidance niche, CIVCO focuses on needle guides and interfaces for transperineal techniques; their products are high relevance as clinicians transition away from transrectal approaches.

• GE HealthCare — A key player in image-fusion navigation, GE’s investment in MRI-ultrasound fusion platforms creates a pathway to capture device attach rates and long-term service revenue with image-guided biopsy adoption.

• Hologic, Inc. — Competes across biopsy instruments and integrated procedural platforms, targeting centers of excellence and high-volume practices with comprehensive solution sets.

• Perineologic Inc. — A focused transperineal access-system developer, Perineologic is an example of how specialized technology can create a defensible niche as practice patterns shift.

• URO-1, Inc. — A recent example of rapid systemwide adoption, URO-1’s SUREcore and coreCARE solutions demonstrate how integrated device–workflow value can accelerate procurement across hospital networks when paired with compelling evidence and total-cost-of-care arguments.

These vendor positions are examined in the report through product roadmaps, pricing strategies, contract types, and M&A prospects. We quantify competitive concentration and show where gap opportunities exist for product differentiation and vertical integration.

What PW Consulting’s report contains — practical, action-oriented deliverables

This release is a strategic brief; the full report provides operational datasets, decision tools and scenario-based models designed for immediate use in boardroom and commercial planning sessions. Highlights include:

• Transparent market-sizing with historical reconciliation (2020–2025) and granular forecast scenarios (2026–2032) that model adoption velocity by procedural approach and technology integration assumptions.

• Competitive benchmarking with product feature mapping, pricing tiers and contract archetypes.

• Reimbursement and coding playbook aligned to the 2026 CPT rearchitecture, including billing workflows and payer negotiation tactics.

• Clinical evidence and KOL landscape: RCTs, registry signals, and trial-to-market timelines that inform reimbursement and adoption timing.

• Service economics, consumables models, and margin simulations for reusable vs disposable strategies.

• Go-to-market playbooks (hospital systems, ambulatory surgical centers, diagnostic networks) and an M&A screening framework for roll-up or bolt-on targets.

To preserve the strategic advisory value of the full deliverable we intentionally withhold detailed subsegment-by-region and application tables from this brief; the full dataset and downloadable spreadsheets are available in the comprehensive report.

Strategic priorities and tactical recommendations for 2026

Based on scenario analysis and vendor interviews, PW Consulting recommends the following priority actions for commercial and corporate leaders planning for 2026:

• Prioritize transperineal-ready product development and clinical evidence generation — the reimbursement landscape and infection-risk concerns create a clear runway for transperineal solutions.

• Build an imaging+device bundling strategy — partner or integrate with MRI/ultrasound fusion and navigation vendors to offer turnkey diagnostic workflows that capture higher attach rates.

• Develop a coding and reimbursement task force — align product labeling, clinical protocols and economic models to the new CPT structure and expedite payer discussions with value dossiers.

• Design flexible contracting packages — offer hospitals predictable total-cost-of-care contracts (capitated consumables, service warranties and upgrade paths) that align with systemwide purchasing processes.

• Invest in AI and pathology partnerships — integration with AI-enabled histopathology and decision-support systems improves diagnostic throughput and strengthens procurement arguments.

• Run targeted RWE pilots in high-volume health systems — capture infection, diagnostic yield and episode-cost metrics to accelerate adoption across peer networks.

• Optimize pricing for bundled CPT economics — model scenarios for single-procedure reimbursement that incorporate capital amortization, consumable attach rates and service revenue.

• Pursue focused M&A only where strategic fit is clear — prioritize targets that add navigation, disposables scale, or RWE capabilities rather than broad market share buys.

• Strengthen supply-chain resilience for single-use products — consumable continuity is a purchasing requirement in many health systems and a leverage point in contracting.

• Engage early with hospital value analyses — leverage hospital case studies (including recent systemwide adoptions) to create peer-to-peer credibility and accelerate decision cycles.

How to use the report in boardroom conversations

For leadership teams preparing 2026 plans, this study is a tactical instrument: use the market scenarios to stress-test revenue forecasts, the reimbursement playbook to inform contract terms, and the competitor benchmarking to prioritize R&D and commercial investments. The included M&A screen and target profiles shorten diligence timelines and focus attention on assets that materially shift go-to-market economics.

Next steps — where to get the full intelligence

This briefing intentionally highlights the strategic implications of our findings while preserving the full analytical dataset and detailed subsegment forecasts for licensed report users. For teams ready to convert insight into action, the full PW Consulting Prostate Biopsy Devices Market report provides the downloadable spreadsheets, regional and application-level scenarios, vendor scorecards and the step-by-step implementation roadmap needed to execute in 2026.

For detailed analysis of this topic, please visit the official page: Prostate Biopsy Devices Market

Lacy Lee
Senior Marketing Manager
sales@pmarketresearch.com
00852-95632430
PW Consulting: www.pmarketresearch.com